ORAMED PHARMACEUTICALS INC. ORMP
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
7.8
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.0M | $64.0M | $13,000 | -$9.2M | $199.7M |
| 2024 | — | -$19.1M | — | -$8.4M | $145.3M |
| 2023 | $1.3M | $5.1M | — | -$10.5M | $162.9M |
| 2022 | $2.7M | -$36.6M | — | -$28.4M | $151.2M |
| 2021 | $2.7M | -$23.0M | — | -$21.6M | $116.5M |
| 2020 | $2.7M | -$11.5M | — | -$12.5M | $32.9M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.8 (safe)
- Working capital / assets 0.495
- Retained earnings / assets -0.535
- EBIT / assets -0.065
- Equity / liabilities 6.419
Source: SEC EDGAR filings · CIK 0001176309 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.